Get the Stockscreener App
2.92
10.19%
0.27
After Hours:
2.91
-0.010
-0.34%
Leap Therapeutics Inc stock is traded at $2.92, with a volume of 379.39K.
It is up +10.19% in the last 24 hours and down -18.89% over the past month.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$2.65
Open:
$2.71
24h Volume:
379.39K
Relative Volume:
1.42
Market Cap:
$101.54M
Revenue:
$1.50M
Net Income/Loss:
$-81.41M
P/E Ratio:
-0.4485
EPS:
-6.51
Net Cash Flow:
$-43.75M
1W Performance:
+12.74%
1M Performance:
-18.89%
6M Performance:
+22.69%
1Y Performance:
+12.31%
1-Day Range:
$2.59
$3.06
1-Week Range:
$2.47
$3.06
52-Week Range:
$1.68
$5.00
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
2.92 | 101.54M | 1.50M | -81.41M | -43.75M | -6.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference - StreetInsider.com
LEAP-012 Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma - The ASCO Post
Leap Therapeutics CEO to Present at Piper Sandler Healthcare Conference | LPTX Stock News - StockTitan
HC Wainwright Reaffirms Buy Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Balyasny Asset Management L.P. Reduces Stake in Leap Therapeutics Inc - GuruFocus.com
Leap Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Leap Therapeutics Reports Wider Q3 Loss, Advances Cancer Drug Trials with $62.8M Cash | LPTX Stock News - StockTitan
Liquor, Wine, Beer: Which Comes With the Worst Lifestyle? - 69News WFMZ-TV
Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales - FiercePharma
Sermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, - GlobeNewswire
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - The ASCO Post
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Payment processor Finix secures $75m in Series C funding - Electronic Payments International
Astellas nabs class-first FDA approval for CLDN18.2 gastric cancer med Vyloy - FiercePharma
Dow Jones notches new record, chip stocks leap higher - Yahoo Finance
Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC) - Defense World
Profire Energy, Inc. (NASDAQ:PFIE) Shares Sold by Marshall Wace LLP - Defense World
Marshall Wace LLP Makes New Investment in Vivid Seats Inc. (NASDAQ:SEAT) - Defense World
Venous Leg Ulcers Treatment Market value, Innovations Driving Market Evolution (2024-2036) - Third Eye News
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - The Malaysian Reserve
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Advances in Sickle Cell Disease: New Gene Therapies and Management Strategies - Pharmacy Times
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Lilly adds to genetic meds push with Genetic Leap alliance - pharmaphorum
Genetic Leap and Lilly Enter Collaboration to Accelerate Genetic Medicine Development with AI - PR Newswire
Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis - Defense World
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight - PR Newswire UK
ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView
Lululemon Athletica (NASDAQ:LULU) Price Target Lowered to $326.00 at Morgan Stanley - Defense World
Farther Finance Advisors LLC Has $1.20 Million Stake in Paychex, Inc. (NASDAQ:PAYX) - Defense World
Laramide Resources Ltd. (TSE:LAM) Director Buys C$10,200.00 in Stock - Defense World
Rothschild Investment LLC Buys Shares of 8,904 Capital Group Growth ETF (NYSEARCA:CGGR) - Defense World
Picton Mahoney Asset Management Takes $71,000 Position in American Woodmark Co. (NASDAQ:AMWD) - Defense World
Rothschild Investment LLC Makes New Investment in iShares Core MSCI Europe ETF (NYSEARCA:IEUR) - Defense World
Farther Finance Advisors LLC Has $1.36 Million Stake in McKesson Co. (NYSE:MCK) - Defense World
Intel Co. (NASDAQ:INTC) Shares Purchased by Farther Finance Advisors LLC - Defense World
Rothschild Investment LLC Takes Position in BlackRock MuniHoldings Quality Fund II, Inc. (NYSE:MUE) - Defense World
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Stock Holdings in Universal Health Services, Inc. (NYSE:UHS) - Defense World
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):